What is Auro Laboratories Ltd (530233) share price return in the past 10 years?

Auro Laboratories Ltd share price has appreciated 27.1% annually (CAGR) over the past ten years.

What is the share price of Auro Laboratories Ltd (530233)?

Company share prices are keep on changing according to the market conditions. The current trading price of Auro Laboratories Ltd (530233) on 04-Jun-2026 16:59:59 at 16:59 is 256.90.

What is the P/E ratio of Auro Laboratories?

The latest standalone P/E ratio of Auro Laboratories as of 04-Jun-2026 is 45.32.

What is the P/B ratio of Auro Laboratories Ltd (530233)?

The latest standalone P/B ratio of Auro Laboratories Ltd (530233) as of 04-Jun-2026 is 3.45.

What is the 52-week high and low of Auro Laboratories Ltd (530233)?

The 52-week high of Auro Laboratories Ltd (530233) is Rs. 317.00 and the 52-week low is Rs. 159.00.

Auro Laboratories Ltd (530233) Share Analysis – Quality, Pipeline & Valuation Zone & DeciZen Rating

Name: Auro Laboratories Ltd (530233)
Brand: Auro Laboratories

Auro Laboratories Ltd (530233)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 530233 NSE: Pharmaceuticals & Drugs | Small Cap | Auro Laboratories Share Price

Auro Laboratories Ltd (530233)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 530233 NSE: Pharmaceuticals & Drugs | Small Cap | Auro Laboratories Share Price

Key Metrics

Valuation Multiples

Market Cap

₹160 Cr.

Current Price

₹256.9

52-Week Low / High

₹159 / 317

TTM EPS

₹5.7

TTM Sales

₹30.7 Cr.

Book Value per Share

₹74.4

P/E Ratio

45.32

Higher than its 5-year historical median

Industry PE

46.5

Price to Book (P/B)

3.45

Higher than its 5-year historical median

Price to Sales (P/S)

5.21

Higher than its 5-year historical median

EV/EBITDA

14.85

Higher than its 5-year historical median

Dividend Yield

0.00%

Profitability Efficiency

Return on Equity (ROE)

4.33%

Underperforms industry median

Return on Capital Employed (ROCE)

3.79%

Underperforms industry median

Return on Assets (ROA)

1.99%

Operating Profit Margin

17.5%

Net Profit Margin

9.48%

Gross Profit Margin

15.4%

Growth Momentum
1-yr vs 3-yr growth

Sales Growth (1 Year)

Slowing versus 3-year growth rate

-63.83%

Operating Profit Growth (1 Year)

Slowing versus 3-year growth rate

-68.13%

Net Profit Growth (1 Year)

Improving versus 3-year growth rate

-76.38%

Asset Quality

Promoter Holding

52.18%

Pledged shares (%) of Promoter's holding (%)

0.00%

Reserves

₹40 Cr.

Equity

₹6.2 Cr.

Face Value

₹10

All Time Low / High

₹0.70 / 317.00

Auro Laboratories stock performance

Key Ratios

Check Before You Invest

Quality

Locked

Valuation

Locked

Price Trend

Locked

Q.1 Is Auro Laboratories Ltd a good quality company?

Auro Laboratories Ltd is a average quality company, based on a somewhat consistent multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.

How does Auro Laboratories Ltd performance compare with that of its Peers?

Q.1 Revenue growth of Auro Laboratories Ltd vs industry peers?

Auro Laboratories Ltd revenue CAGR is -15.03%, compared to the industry median CAGR of 5.35%, indicating slower growth and losing its market share.

Q.1 Promoter shareholding and pledge status of Auro Laboratories Ltd?

Promoters hold 52.18% of the Auro Laboratories Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Q.1 Stock return of Auro Laboratories Ltd over the last decade?

Over the last 9 year(s), the stock has delivered a CAGR of 28.4% based on the current price.

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	11.2%	20.2%	28.7%	29.1%	24.8%	38.9%	12.2%	9.9%	20.4%	3.8%	-
Value Creation Index ⓘ	-0.2	0.5	1.1	1.1	0.8	1.8	-0.1	-0.3	0.5	-0.7	-
Growth Parameters ⓘ
Sales ⓘ	27.9	35.5	40.8	46.8	43.8	54.3	50.9	52.9	53.6	19.4	31
Sales YoY Gr.	-	27.1%	15%	14.8%	-6.5%	23.9%	-6.2%	4%	1.4%	-63.8%	-
Adj EPS ⓘ	1	0.8	5.2	6.1	5.5	10.9	3.7	3	10.9	2.3	5.7
YoY Gr.	-	-24.3%	561.5%	18%	-9%	96.2%	-65.7%	-20.1%	265.4%	-78.9%	-
BVPS (₹) ⓘ	13.8	15.1	20.8	27.9	34.5	45.9	50.6	54.9	67.3	68.9	74.4
Adj Net Profit ⓘ	0.6	0.5	3.2	3.8	3.5	6.8	2.3	1.9	6.8	1.4	4
Cash Flow from Ops. ⓘ	7.9	5.9	4.8	6.9	9.3	12.8	-6.6	3.3	18.8	5.8	-
Debt/CF from Ops. ⓘ	1.6	1.7	1.9	1.2	0.3	0.3	-2.1	2	1.4	7.8	-

CAGR ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	-4%	-15%	-27.5%	-63.8%
Adj EPS ⓘ	9.3%	-16.1%	-14.9%	-78.9%
BVPSⓘ	19.6%	14.9%	10.9%	2.4%
Share Price	27.1%	19.4%	44.7%	-10.4%

Key Financial Parameters ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	7.9	5.4	28.7	25	17.7	27.1	7.7	5.7	17.8	3.4	7.9
Op. Profit Mgn % ⓘ	10	12.5	15.6	14.9	14.3	20.7	9.1	8.3	19.9	17.6	31.7
Net Profit Mgn % ⓘ	2.3	1.4	7.9	8.1	7.9	12.5	4.6	3.5	12.7	7.4	11.5
Debt to Equity ⓘ	1.5	1.1	0.7	0.5	0.2	0.1	0.4	0.2	0.6	1.1	0
Working Cap Days ⓘ	188	124	119	112	112	87	139	202	212	471	115
Cash Conv. Cycle ⓘ	91	39	29	37	39	20	58	84	81	109	-23

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	28	35	41	47	44	54	51	53	54	19
Operating Expenses ⓘ +	25	31	34	40	38	43	46	49	43	16
Manufacturing Costs	2	3	3	3	3	4	3	4	4	1
Material Costs	18	22	25	29	24	29	33	36	27	9
Employee Cost	2	3	3	3	3	4	4	4	4	2
Other Costs ⓘ	3	3	4	5	6	7	6	6	8	3
Operating Profit ⓘ	3	4	6	7	6	11	5	4	11	3
Operating Profit Margin (%)	10.0%	12.5%	15.6%	14.9%	14.3%	20.7%	9.1%	8.3%	19.9%	17.5%
Other Income ⓘ +	0	1	1	1	1	1	1	1	2	1
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	0	0
Interest ⓘ	2	1	1	1	1	0	1	1	1	1
Depreciation ⓘ	1	1	1	1	1	1	1	1	1	1
Profit Before Tax ⓘ	1	3	5	6	6	11	4	3	10	2
Tax ⓘ	0	2	1	2	2	3	1	1	3	0
Profit After Tax	1	1	4	4	4	7	3	2	8	2
PAT Margin (%)	3.2%	2.3%	8.7%	9.4%	9.3%	13.2%	5.6%	4.6%	14.5%	9.5%
Adjusted EPS (₹)	1.4	1.3	5.7	7.1	6.5	11.5	4.6	3.9	12.5	3.0
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Valuation of Auro Laboratories - Standalone

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	9	9	13	17	21	29	32	34	42	43
Share Capital ⓘ	6	6	6	6	6	6	6	6	6	6
Reserves ⓘ	2	3	7	11	15	22	25	28	36	37
Debt +	13	10	9	8	3	3	13	6	26	43
Long Term Debt	7	10	6	5	3	2	2	2	18	33
Short Term Debt	5	0	3	4	0	1	12	4	8	10
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	4	5	5	5	5	6	5	11	6	6
Others Liabilities ⓘ	1	3	3	3	3	5	5	4	11	6
Total Liabilities ⓘ	26	27	30	33	32	42	55	56	86	99
Fixed Assets
Net Fixed Assets ⓘ +	9	13	13	15	14	14	14	13	22	21
Gross Block	15	20	21	23	24	24	25	25	36	36
Accumulated Depreciation	6	7	8	9	10	11	12	13	14	15
CWIP ⓘ	3	0	1	0	0	0	4	8	33	56
Investments ⓘ	0	0	0	0	0	0	0	0	0	0
Inventories	4	1	1	3	4	3	4	12	8	4
Trade Receivables	5	8	8	9	6	7	14	12	13	9
Cash Equivalents	1	1	2	4	6	15	12	2	2	1
Others Assets ⓘ	3	4	4	3	2	4	7	9	8	8
Total Assets ⓘ	26	27	30	33	32	42	55	56	86	99

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	8	6	5	7	9	13	-7	3	19	6
PBT ⓘ	1	3	5	6	6	11	4	3	10	2
Adjustment ⓘ	2	2	2	2	2	1	2	2	2	2
Changes in Working Capital ⓘ	5	2	-1	-1	2	1	-12	-2	6	2
Tax Paid ⓘ	0	-1	-1	0	0	0	0	0	0	0
Cash Flow From Investing Activity ⓘ +	-2	-2	-2	-3	-2	-4	-5	-5	-39	-24
Capex	-3	0	-2	-2	-1	-0	-5	-4	-36	-24
Net Investments	0	0	0	0	0	0	0	0	0	0
Others ⓘ	0	-2	0	-2	-2	-3	-1	-1	-3	-1
Cash Flow From Financing Activity ⓘ +	-5	-4	-2	-2	-6	-0	10	-8	19	18
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	-0	-1	0	-1	-1	-0	-0	1	17	15
Interest Paid ⓘ	-2	-1	-1	-1	-1	-0	-1	-1	-1	-1
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Others ⓘ	-4	-2	-1	-0	-4	0	11	-8	3	4
Net Cash Flow ⓘ	0	0	1	2	2	9	-2	-10	-1	-1

Financial Ratio

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	10.83	9.06	31.53	28.95	20.84	28.67	9.47	7.43	20.46	4.33
ROCE (%)	11.21	20.24	28.65	29.12	24.8	38.88	12.2	9.92	20.37	3.79
Asset Turnover Ratio	1.08	1.41	1.43	1.47	1.33	1.46	1.05	0.95	0.76	0.21
PAT to CFO Conversion(x)	8	6	1.25	1.75	2.25	1.86	-2.33	1.5	2.38	3
Working Capital Days
Receivable Days	83.80	62.80	71.90	65.80	59.50	44	75	89.80	87.80	214.40
Inventory Days	61.30	27.80	12.60	19	31	22.20	24.40	55.20	68	112
Payable Days	71.30	69.30	75.50	66.90	74	67.10	59.10	83.60	121.50	246.20

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Auro Laboratories Ltd FAQs

The current trading price of Auro Laboratories on 04-Jun-2026 16:59 is ₹256.9.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 03-Jun-2026 the market cap of Auro Laboratories stood at ₹160.1 Cr

The latest P/E ratio of Auro Laboratories as of 03-Jun-2026 is 45.32.

The latest P/B ratio of Auro Laboratories as of 03-Jun-2026 is 3.45.

The 52-week high of Auro Laboratories is ₹317.0 and the 52-week low is ₹159.0.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Auro Laboratories is ₹30.74 ( Cr.) .

Past 10 year's financial track record analysis by Moneyworks4me indicates that Auro Laboratories Ltd is a average quality company.

The key valuation ratios of Auro Laboratories Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Auro Laboratories Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

About Auro Laboratories Ltd

Auro Laboratories incorporated in 1989 is engaged in business of manufacturing active pharmaceutical ingredients (API's), intermediates and generic formulations. The company is promoted by Shri Sharat Deorah and Shri Satish Deorah.

Companyâ€™s manufacturing facility is located at Tarapur in the state of Maharashtra. This facility is well supported by quality control laboratory and common effluent treatment plant (CETP). The Company started commercial production of this facility on 14th July, 1992. The manufacturing facility has an installed capacity in excess of 500 tonnes per annum.

Company is primarily focused on manufacturing anti-diabetic drugs. Presently company caters its products in therapeutic segment such as antihistamine, anti-fungal, anti-ulcer, anti-malaria, anti-inflammatory, antacids and others. Company exports its products in countries like Egypt, Germany, Malaysia, Singapore, South Africa, Brazil, Spain and United Kingdom. Auro Laboratories received ISO 9001:2000 and WHO - cGMP certifications for its quality management.

Products

APIs- Under this company manufactures drugs like Chlorpheniramine Maleate, Chlorzoxazone, Metformin HCl, Potassium Iodate, Magnesium Hydroxide and many more.

Under specialty chemicals company manufactures Guanidine Nitrate, Dimethyl Amine HCl, 2-Ethoxy Benzoic Acid and 3,4,5, Trimethoxy Benzoic Acid.

Intermediate- Company manufactures products such as Glibenclamde Sulphonamide, Cis-bramo benzoate, Cls-Tosylate, Cis-bramo benzoate, 3, 4, 5 - Trimethoxy Benzoic Acid, 2-Ethoxy Benzoic Acid and 5-Bromo Phthalide

Milestones

1992- Company started manufacturing of Sodium Citrate and Potassium Iodide. Company developed antibacterial drug, Trimethoprim.

1996- Company commenced manufacturing of 3,4,5 Trimethoxy Benzaldehyde, which is the basic raw material for Trimethoprim. Company was listed on Bombay Stock Exchange (BSE).

2004-Company received ISO 9001:2000 certification.

2006-Company received certificate of suitability (cos) from the European Directorate of Quality Medicine (EDQM).

2007- Company received DMF No 19910 from the FDA for Metformin Hydrochloride.

Future plansAuro Laboratories plans to widen its product portfolio to strengthen its position in the market.

Auro Laboratories Ltd (530233)

Auro Laboratories Ltd (530233)

Auro Laboratories stock performance

Check Before You Invest

Quality

Valuation

Price Trend

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of Auro Laboratories - Standalone

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Auro Laboratories Ltd FAQs

About Auro Laboratories Ltd

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Auro Laboratories Ltd (530233)

Auro Laboratories Ltd (530233)

Auro Laboratories stock performance

Check Before You Invest

Quality

Valuation

Price Trend

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of Auro Laboratories - Standalone

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Auro Laboratories Ltd FAQs

What is the share price of Auro Laboratories?

What is the market cap of Auro Laboratories?

What is the P/E ratio of Auro Laboratories?

What is the P/B ratio of Auro Laboratories?

What is the 52-week high and low of Auro Laboratories?

What is the TTM revenue of Auro Laboratories?

Is Auro Laboratories Ltd a good quality company?

Is Auro Laboratories Ltd undervalued or overvalued?

Is Auro Laboratories Ltd a good buy now?

About Auro Laboratories Ltd

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.